Peptide nucleic acid

Synthesis of Peptide-Peptide Nucleic Acid Conjugates, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, August 19, 2021
Industry, Peptide, Peptide nucleic acid, University, Therapy, Jiangsu University, Symphony, Efficiency, DNA, RNA, PNA, Solubility, University of Porto, Food, SPPS, Fine chemical

PNAs hybridize with complementary nucleic acid segments with higher affinity and specificity than natural ON, interfering with higher efficiency with target genes.

Key Points: 
  • PNAs hybridize with complementary nucleic acid segments with higher affinity and specificity than natural ON, interfering with higher efficiency with target genes.
  • For more information, or to register for this event, visit Synthesis of Peptide-Peptide Nucleic Acid Conjugates.
  • Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community.
  • Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

NeuBase Therapeutics Announces Addition of Peter Nielsen, Ph.D., Inventor of Peptide Nucleic Acid Technology, to Scientific Advisory Board

Retrieved on: 
Tuesday, October 13, 2020
Origin of life, Peptide nucleic acid, Dietrich Stephan, Biotechnology, Life sciences, Biology

PITTSBURGH, Oct. 13, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (NeuBase or the Company), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced the addition of Peter Nielsen, Ph.D. to its scientific advisory board.

Key Points: 
  • PITTSBURGH, Oct. 13, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (NeuBase or the Company), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced the addition of Peter Nielsen, Ph.D. to its scientific advisory board.
  • Dr. Nielsen, the primary inventor of peptide nucleic acid (PNA) technology, brings extensive experience in genetic medicine to NeuBase as the Company optimizes its PATrOL therapies and moves them towards the clinic.
  • We are honored to welcome Dr. Nielsen, a transformational leader in the field of genetics and genomic technologies, to the NeuBase scientific advisory board.
  • I look forward to working with the team and lending my guidance as NeuBase progresses its first-in-class medicines.

NeuBase Therapeutics to Present at the BTIG Virtual Biotechnology Conference on Tuesday, August 11th

Retrieved on: 
Thursday, July 30, 2020
Branches of biology, Biology, Molecular biology, DNA, RNA, Nucleic acids, Biotechnology, Sense, Oligonucleotide, Gene silencing, Antisense therapy, Peptide nucleic acid

NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides.

Key Points: 
  • NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides.
  • The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of secondary RNA structures.
  • Using PATrOL technology, NeuBase aims to first tackle rare, genetic diseases.

NeuBase Therapeutics to Present at the Stifel 2019 Healthcare Conference

Retrieved on: 
Tuesday, November 12, 2019
Branches of biology, Biology, RNA, DNA, Molecular biology, Gene expression, Nucleic acids, Sense, Oligonucleotide, Gene silencing, Antisense therapy, Peptide nucleic acid

NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides.

Key Points: 
  • NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides.
  • The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of genomic loci or secondary and tertiary RNA structures.
  • Using PATrOL technology, NeuBase aims to first tackle rare, genetic neurological disorders.

NeuBase Therapeutics to Present at the Chardan 3rd Annual Genetic Medicines Conference

Retrieved on: 
Thursday, September 26, 2019
Branches of biology, Biology, RNA, DNA, Molecular biology, Gene expression, Nucleic acids, Sense, Oligonucleotide, Gene silencing, Antisense therapy, Peptide nucleic acid

NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides.

Key Points: 
  • NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides.
  • The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of genomic loci or secondary and tertiary RNA structures.
  • Using PATrOL technology, NeuBase aims to first tackle rare, genetic neurological disorders.

Global RNAi Technologies, Markets & Companies Research Report 2019 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 12, 2019
Biotechnology, Genetics, Health, Branches of biology, RNA, Biology, Nucleic acids, Gene expression, Molecular biology, DNA, RNA interference, Aptamer, Oligonucleotide, Sense, Peptide nucleic acid

The "RNAi - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "RNAi - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • The report compares RNAi with other antisense approaches using oligonucleotides, aptamers, ribozymes, peptide nucleic acid and locked nucleic acid.
  • RNAi microarray has been devised and can be tailored to meet the needs for high throughput screens for identifying appropriate RNAi probes.
  • The major use of RNAi reagents is in research but it partially overlaps that of drug discovery and therapeutic development.

Molecular Diagnostics Markets, 2018-2019 & 2028 - Focus on PCR, FISH, PNA, Electrochemical Detection of DNA, Sequencing, Mitochondrial DNA, Biochips, Nanotechnology and Proteomic Technologies

Retrieved on: 
Thursday, May 23, 2019
Branches of biology, Biology, Life sciences, Molecular biology, Biotechnology, Laboratory techniques, Molecular diagnostics, Peptide nucleic acid, Nucleic acid hybridization, Polymerase chain reaction, Fluorescence in situ hybridization, Biochip

This includes several polymerase chain reaction (PCR)-based technologies, fluorescent in situ hybridization (FISH), peptide nucleic acids (PNA), electrochemical detection of DNA, sequencing, mitochondrial DNA, biochips, nanotechnology and proteomic technologies.

Key Points: 
  • This includes several polymerase chain reaction (PCR)-based technologies, fluorescent in situ hybridization (FISH), peptide nucleic acids (PNA), electrochemical detection of DNA, sequencing, mitochondrial DNA, biochips, nanotechnology and proteomic technologies.
  • Initial applications of molecular diagnostics were mostly for infections but are now increasing in the areas of genetic disorders, preimplantation screening and cancer.
  • Molecular diagnostics is being combined with therapeutics and forms an important component of integrated healthcare.
  • Molecular diagnostic technologies are also involved in the development of personalized medicine based on pharmacogenetics and pharmacogenomics.